Related Experiment Video
Updated: May 28, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Gene expression signatures and ex vivo drug sensitivity profiles in children with acute lymphoblastic leukemia
Joanna Szczepanek1, Michal Jarzab, Malgorzata Oczko-Wojciechowska
1Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. szczepanekjoanna@gmail.com
Introduction:
Causes of treatment failure in acute lymphoblastic leukemia (ALL) are still poorly understood. Microarray technology gives new possibilities for the analysis of the biology of leukemias. We hypothesize that drug sensitivity in pediatric ALL is driven by specific molecular mechanisms that correlate with gene expression profiles assessed by microarray analysis.
Objective:
The aim of the study was to determine the ex vivo resistance profiles of 20 antileukemic drugs and gene expression profiles, with relation to response to initial therapy.
Patients And Methods:
Lymphoblasts were analyzed after bone marrow biopsy was obtained from 56 patients. The profile of in vitro resistance to drugs was determined in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) cytotoxicity assay. High-quality total RNA was prepared and hybridized to oligonucleotide arrays HG-U133A 2.0 Chip (Affymetrix). The expression of selected genes was tested by qualitative reverse transcription polymerase chain reaction (qRT-PCR).
Results And Conclusions:
The exposure of leukemic blasts to drugs initiates a complex cellular response, which reflects global changes in gene expression. Changes in the expression of several genes are highly correlated with drug resistance.
Insights
Gene expression profiles in pediatric acute lymphoblastic leukemia (ALL) correlate with drug resistance. Understanding these molecular mechanisms can improve treatment strategies for ALL.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Treatment failure in acute lymphoblastic leukemia (ALL) is not fully understood.
- Microarray technology offers new insights into leukemia biology.
- Drug sensitivity in pediatric ALL may be linked to specific molecular mechanisms.
Purpose of the Study:
- To determine ex vivo resistance profiles of 20 antileukemic drugs.
- To analyze gene expression profiles in relation to initial therapy response.
- To investigate molecular drivers of drug sensitivity in pediatric ALL.
Main Methods:
- Analyzed lymphoblasts from 56 pediatric ALL patients.
- Assessed in vitro drug resistance using the MTT cytotoxicity assay.
- Performed microarray analysis (Affymetrix HG-U133A 2.0 Chip) and qRT-PCR for gene expression.
Main Results:
- Drug exposure in leukemic blasts triggers complex cellular responses.
- Global gene expression changes were observed.
- Specific gene expression alterations strongly correlate with drug resistance.
Conclusions:
- Gene expression profiles are linked to drug resistance in pediatric ALL.
- Identifying these molecular mechanisms is crucial for understanding treatment failure.
- This study provides a foundation for developing targeted therapies.
More Related Videos
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
12:58Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
